ATE362770T1 - Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen - Google Patents

Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Info

Publication number
ATE362770T1
ATE362770T1 AT01909098T AT01909098T ATE362770T1 AT E362770 T1 ATE362770 T1 AT E362770T1 AT 01909098 T AT01909098 T AT 01909098T AT 01909098 T AT01909098 T AT 01909098T AT E362770 T1 ATE362770 T1 AT E362770T1
Authority
AT
Austria
Prior art keywords
relaxin
diseases
vaso
construction
treatment
Prior art date
Application number
AT01909098T
Other languages
English (en)
Inventor
Kirk Conrad
Martyn Lewis
Elaine Unemori
Xinfan Huang
Carol Tozzi
Original Assignee
Bas Medical Inc
Univ Pittsburgh
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bas Medical Inc, Univ Pittsburgh, Univ New Jersey Med filed Critical Bas Medical Inc
Application granted granted Critical
Publication of ATE362770T1 publication Critical patent/ATE362770T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01909098T 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen ATE362770T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18140800P 2000-02-09 2000-02-09
US20028400P 2000-04-28 2000-04-28
US24221600P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
ATE362770T1 true ATE362770T1 (de) 2007-06-15

Family

ID=27391410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909098T ATE362770T1 (de) 2000-02-09 2001-02-09 Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen

Country Status (7)

Country Link
US (2) US6723702B2 (de)
EP (1) EP1253929B1 (de)
AT (1) ATE362770T1 (de)
AU (1) AU2001236886A1 (de)
CA (1) CA2397200C (de)
DE (1) DE60128540T2 (de)
WO (1) WO2001058468A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131644T2 (de) * 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ITFI20030328A1 (it) * 2003-12-24 2005-06-25 Mario Bigazzi Uso della relaxina come adiuvante nella differenziazione
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1765149B1 (de) * 2004-03-19 2016-09-28 University Of Pittsburgh Verwendung von relaxin zur erhöhung der arteriencompliance
EP1729817B1 (de) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Relaxin-gen enthaltendes genverabreichungssystem und pharmazeutische zusammensetzung, die relaxin verwendet
JP4836942B2 (ja) 2004-04-30 2011-12-14 コーセラ， インコーポレイテッド リラキシンの調節による胎仔の発育の制御のための方法および組成物
EP1846443A4 (de) * 2005-01-07 2008-07-23 Glaxo Group Ltd Neuartige verwendung
US7893244B2 (en) 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
ZA200900316B (en) * 2006-07-25 2010-05-26 Alcon Res Ltd Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for prevention and treatment of ocular disorders
WO2008140682A1 (en) * 2007-05-11 2008-11-20 Corning Incorporated Isopipe sag control using improved end support conditions
CA2724540C (en) * 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
MX2010012454A (es) * 2008-05-16 2011-03-29 Corthera Inc Star Metodo para promover la curacion de heridas.
BRPI0920897A2 (pt) 2008-11-24 2015-12-29 Corthera Inc prognóstico e prevenção de pré-eclampsia
WO2010105081A1 (en) * 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
EP2544706B1 (de) 2010-03-10 2015-06-17 The University Of Melbourne Modulierung von aquaporinen mit relaxin
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
RU2014103288A (ru) * 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
WO2013033324A2 (en) * 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
MX2015001488A (es) * 2012-07-31 2015-04-08 Novartis Ag Tratamiento de la inflamacion utilizando serelaxina.
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
BR112023007024A2 (pt) * 2020-10-15 2023-10-03 Univ Northeastern Células modificadas para produção aumentada de colágeno
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
DE3236264A1 (de) * 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg Verfahren zur gewinnung von relaxin
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
AU626840B2 (en) * 1988-02-26 1992-08-13 Genentech Inc. Human relaxin formulation
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5952296A (en) * 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
JPH09502726A (ja) 1993-09-14 1997-03-18 マリンクロット・メディカル・インコーポレイテッド 血管障害を防ぐポリペプチドを用いる治療的処置
CA2229479C (en) * 1995-08-15 2010-03-30 Connective Therapeutics, Inc. Method of promoting angiogenesis
US6251863B1 (en) * 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin

Also Published As

Publication number Publication date
US6723702B2 (en) 2004-04-20
US20040266685A1 (en) 2004-12-30
EP1253929A4 (de) 2003-03-05
CA2397200A1 (en) 2001-08-16
US20020019349A1 (en) 2002-02-14
EP1253929A1 (de) 2002-11-06
DE60128540T2 (de) 2008-01-31
DE60128540D1 (de) 2007-07-05
HK1051001A1 (en) 2003-07-18
WO2001058468A1 (en) 2001-08-16
CA2397200C (en) 2010-11-23
EP1253929B1 (de) 2007-05-23
AU2001236886A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
ATE362770T1 (de) Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
ATE371462T1 (de) Verbesserung der herstellung von endogenen gonadotropin
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
ATE312635T1 (de) Ventilanordnung
PE20001032A1 (es) Composiciones y metodos para tratar enfermedades pulmonares
TR200101120T2 (tr) Serin proteaz inhibitörü
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE60143990D1 (de) Neue therapeutische verwendung von smr-1 peptide
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE454155T1 (de) Verwendung von drospirenon zur behandlung von hypertension
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE324112T1 (de) Topische behandlung bei der mastalgie
DE60334556D1 (de) Chorionic gonadotropin zur Behandlung des chronischen Schmerzsyndroms des Beckens
SE0004101D0 (sv) New use
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
SE9902597D0 (sv) New use
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
EP1854476A3 (de) Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
ATE283059T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von reizbarkeit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1253929

Country of ref document: EP

EEFA Change of the company name